Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Total Assets
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd total assets. Based on the latest financial reports, Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) holds total assets worth ₩177.78 Billion KRW (≈ $120.48 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Daishin Balance No.6 Special Purpose Acq market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (2020–2024)
Total assets of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd from 2020 to 2024. This chart illustrates how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Daishin Balance No.6 Special Purpose Acq stock price for real-time trading data and today's change.
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Asset Composition Analysis
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Total Assets Breakdown (December 2024)
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd total assets breakdown as of December 2024. Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total assets of ₩177.78 Billion consist of 49.6% current assets and 50.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩46.81 Billion | 0.0% |
| Accounts Receivable | ₩28.78 Billion | 13.6% |
| Inventory | ₩26.80 Billion | 12.6% |
| Property, Plant & Equipment | ₩87.36 Billion | 41.2% |
| Intangible Assets | ₩4.41 Billion | 2.1% |
| Goodwill | ₩420.39 Million | 0.2% |
Asset Composition Trend (2020–2024)
This chart illustrates how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Daishin Balance No.6 Special Purpose Acq (307750) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's current assets represent 49.6% of total assets in 2024, a decrease from 67.5% in 2020.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 16.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is property, plant & equipment at 41.2% of total assets.
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Competitors by Total Assets
Key competitors of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs5.47 Billion |
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 1.17 | 3.28 |
| Quick Ratio | 0.81 | 0.95 | 2.57 |
| Cash Ratio | 0.00 | 0.04 | 0.00 |
| Working Capital | ₩9.67 Billion | ₩18.42 Billion | ₩68.58 Billion |
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | ₩212.27 Billion |
| Market Capitalization | $70.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (2020–2024)
The table below shows the annual total assets of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩212.27 Billion ≈ $143.85 Million |
-5.70% |
| 2023-12-31 | ₩225.10 Billion ≈ $152.55 Million |
+14.79% |
| 2022-12-31 | ₩196.10 Billion ≈ $132.89 Million |
+83.29% |
| 2021-12-31 | ₩106.99 Billion ≈ $72.50 Million |
+85.09% |
| 2020-12-31 | ₩57.80 Billion ≈ $39.17 Million |
-- |
About Daishin Balance No.6 Special Purpose Acquisition Co. Ltd
KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic mate… Read more